Intravenous Immunoglobulin Market Size and Forecast 2024-2033|Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A

Overview and Scope

Intravenous immunoglobulin refers to a therapy used for the treatment of immunodeficient people. It is administered in the form of intravenous infusion. Infusion liquid is made from immunoglobulins collected from healthy individuals and purified to eliminate any blood-borne infection or impurity.

Sizing and Forecast

The intravenous immunoglobulin market size has grown strongly in recent years. It will grow from $13.82 billion in 2023 to $14.84 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to treatment of primary immunodeficiency disorders , management of neurological disorders, rising geriatric population, advancements in plasma fractionation techniques, expanded indications in neurology, treatment of infectious diseases, pediatric immunodeficiency treatment.

The intravenous immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $20.24 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing incidence of autoimmune disorders, ongoing research in immunology, rising healthcare expenditure, growth in cancer incidence, innovation in immunoglobulin products, personalized medicine approaches.. Major trends in the forecast period include primary immunodeficiency disorders (pidd) treatment, rapid technological innovations, strategic collaborations and partnerships, advancements in manufacturing processes, indications in neurology, use in hematology, advances in immunotherapy.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Segmentation & Regional Insights

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

North America was the largest region in the intravenous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Major Driver Impacting Market Growth

The increasing geriatric population is expected to drive the intravenous immunoglobulin market forward. The geriatric population refers to the population above 65 years of age. As people grow old, their immunity does not work properly and there is a lack of antibodies. Therefore, they need immunoglobulins to provide them with antibodies. This increases demand for intravenous immunoglobulins and drives the intravenous immunoglobulin market forward. For instance, in 2021, according to the Elderly in India 2021 report by the National Statistical Office (NSO), a statistics wing of the Ministry of Statistics and Programme Implementation of the government of India, in 2021, 138 million elderly people were there in India and the number is expected to rise to 194 million by 2031. Additionally, according to the World Health Organization (WHO), a specialized agency of the United Nations, by 2030, 1 in 6 people in the world will be 60 years or older and the total number of people over 60 years will increase to 1.4 billion by 2030 increasing from 1 billion in 2020. As a result, the increasing geriatric population will drive the growth of the intravenous immunoglobulin market forward.

Key Industry Players

Major companies operating in the intravenous immunoglobulin market report are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bayer AG, LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., Emergent BioSolutions Inc., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

The intravenous immunoglobulin market report table of contents includes:

1. Executive Summary

2. Intravenous Immunoglobulin Market Characteristics

3. Intravenous Immunoglobulin Market Trends And Strategies

4. Intravenous Immunoglobulin Market – Macro Economic Scenario

5. Global Intravenous Immunoglobulin Market Size and Growth

26. South America Intravenous Immunoglobulin Market

27. Brazil Intravenous Immunoglobulin Market

28. Middle East Intravenous Immunoglobulin Market

29. Africa Intravenous Immunoglobulin Market

30. Intravenous Immunoglobulin Market Competitive Landscape And Company Profiles

Top Major Players: